FDA Class II Recall: Inadvertent Distribution of Pfizer-Distributed Inflectra (Infliximab-dyyb) Due to cGMP Deviation
McKesson initiated a Class II recall (D-0213-2025) for 192 vials of Pfizer-distributed Inflectra (infliximab-dyyb) due to cGMP deviations, specifically inadvertent distribution of quarantined product. This event highlights critical vulnerabilities in supply chain quality control and segregation protocols, demanding immediate attention from procurement and regulatory teams to assess internal and partner compliance.
FDA Class II Recall: Inadvertent Distribution of Quarantined Inflectra (Infliximab-dyyb)
On January 17, 2025, McKesson initiated a voluntary Class II recall, designated D-0213-2025, for 192 vials of Inflectra (infliximab-dyyb), a critical human prescription drug. This specific recall pertains to Lot# 04647349, with an expiration date of May 31, 2029. The core issue, identified as a cGMP deviation, involved the inadvertent distribution of product that was explicitly intended for quarantine. This means that a batch of infliximab-dyyb, a tumor necrosis factor blocker, which should have been held back from general distribution due to quality control procedures, was mistakenly released into the U.S. market. The product, manufactured by CELLTRION, INC., and distributed by Pfizer Laboratories Div Pfizer Inc., was distributed nationwide across the USA. For procurement directors, this event necessitates an immediate audit of existing inventories for Lot# 04647349 to prevent any further distribution or use of the affected product. The relatively small quantity of 192 vials suggests a contained incident, but the underlying cGMP failure points to a systemic vulnerability that requires urgent attention to safeguard future supply integrity. Supply chain VPs must recognize that such breaches, even if minor in volume, can erode trust and introduce unforeseen risks into critical medication supply lines.
Commercial and Regulatory Implications of cGMP Protocol Failure for Biologic Supply
The cGMP deviation leading to the recall of Inflectra (infliximab-dyyb) underscores a critical lapse in quality management systems, particularly concerning product segregation and release protocols. For regulatory affairs heads, the inadvertent distribution of quarantined product signals a failure to adhere to stringent FDA cGMP requirements, which mandate robust controls to prevent the release of non-conforming or unapproved materials. While this is a voluntary, firm-initiated recall by McKesson, the incident reflects on the entire supply chain, including the manufacturer CELLTRION, INC., and distributor Pfizer Laboratories Div Pfizer Inc. Such events can trigger heightened regulatory scrutiny, potentially leading to more intensive inspections or demands for comprehensive corrective and preventive actions (CAPA) plans from all involved parties. Business development executives should note that even Class II recalls, indicating a remote probability of serious adverse health consequences, can impact brand reputation and market confidence, influencing future partnership agreements or market access strategies for biologics. Procurement directors must leverage this event to reinforce due diligence on their contract manufacturers and distributors, ensuring that their quality agreements explicitly address and verify robust quarantine, release, and recall procedures for all critical pharmaceutical products. The incident serves as a stark reminder that even with established players, continuous vigilance over cGMP compliance is paramount to mitigate supply chain risks and maintain patient safety.